Skip to content
Menu

Truist Securities Reiterates Buy on Genmab, Raises Price Target to $67

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Truist Securities analyst Gregory Renza reiterates Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $67.

Truist Securities analyst Gregory Renza reiterates Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $67.

Read at benzinga.com